NorthStrive files patents for drugs to protect muscle during weight loss (opens in new tab)

NorthStrive Biosciences, a PMGC Holdings Inc. subsidiary, filed two U.S. patent applications on June 18, 2026, seeking human-use claims for EL-22 and EL-32 to preserve lean muscle mass during GLP-1 and other obesity-related weight loss therapies. The filings, assigned U.S. Patent Application Nos. 19/709,895 (EL-22) and 19/709,950 (EL-32), expand the company’s intellectual property from animal […] The post appeared first on <a href="